MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

Lausanne Researchers Leverage 10x Genomics' Chromium and Xenium Technologies for New Insights into Brain Cancer Resistance and Therapeutic Opportunities

NextEdge Admin

11 Sep 2024

2 min 18 sec

10x Genomics, a leader in single-cell and spatial biology, announced the use of its Chromium Single Cell Gene Expression and Xenium In Situ platforms in a study published in *Cancer Cell*. Led by Professor Johanna Joyce of the University of Lausanne and Ludwig Institute for Cancer Research, the study explored how fibrotic scars contribute to glioblastoma (GBM) recurrence after treatment.

GBM is the most aggressive brain cancer, with a five-year survival rate of less than 5%. In this study, researchers discovered that all GBM treatments induced fibrosis in the brain, with recurrent tumors found adjacent to these scars. Dormant tumor cells within the scars were believed to act as seeds for recurrence. Using Chromium to analyze cell populations and Xenium to locate cells within the scars, the team identified pericyte-derived fibroblast-like cells as key drivers of scar formation.

Further analysis revealed two pathways linked to scar formation that peaked seven days post-treatment. The researchers developed a treatment combining a CSF-1R inhibitor and two drugs targeting scar formation, significantly improving survival rates in mice. Only one in 18 mice experienced recurrence during the trial.

Ben Hindson, Co-Founder of 10x Genomics, emphasized how integrating single-cell spatial and scRNA-seq technologies provided new insights into cancer dynamics, leading to potential therapeutic advancements. Professor Joyce highlighted the potential to enhance GBM patient outcomes by targeting fibrotic scarring, an area of ongoing research in her lab.